Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Apogee Therapeutics Inc (APGE)

$37.75 -0.51 (-1.33%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	1.76B
Revenue (ttm)	0.00
Net Income (ttm)	-182.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	647,300
Avg Vol	970,866
Day's Range	N/A - N/A
Shares Out	46.05M
Stochastic %K	21%
Beta	1.47
Analysts	Strong Sell
Price Target	$96.75

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 394 5230

Website: www.apogeetherapeutics.com

Address:

Building 17, Suite 102b 221 Crescent Street, Waltham, United States

rxptgh Jul. 29 at 7:25 AM

$APGE undervalued Under followed

0 · Reply

StockHunter75 Jul. 28 at 6:28 PM

$APGE bought the dip.

0 · Reply

idk_idk Jul. 28 at 2:52 PM

$APGE gonna be a long wait, but worth it hopefully

0 · Reply

fezziwig2018 Jul. 24 at 3:36 PM

All of my $ATPC and $APGE eventually found its way into $IXHL last week -Cost basis $0.48 - will add on any pullbacks - though I don’t anticipate any.

1 · Reply

gc358 Jul. 23 at 3:44 PM

$APGE With 8.7M short shares comprising 23% of the float, this is primed for a squeeze if we can get some buying pressure.

0 · Reply

StockHunter75 Jul. 23 at 2:38 PM

$APGE buying more.

0 · Reply

amda Jul. 21 at 6:41 PM

$APGE slow and steady upward from under $39..

0 · Reply

amda Jul. 21 at 3:36 PM

$APGE a steal under $40...

0 · Reply

StockHunter75 Jul. 21 at 2:06 PM

$APGE Bullish. Buy the dips

0 · Reply

HodlMaBeer Jul. 21 at 1:47 PM

$APGE release the lion

0 · Reply

Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis

Jul 7, 2025, 6:00 AM EDT - 26 days ago

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Jul 6, 2025, 6:00 PM EDT - 26 days ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

May 29, 2025, 7:30 AM EDT - 2 months ago

Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 12, 2025, 4:04 PM EDT - 2 months ago

Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class

May 12, 2025, 6:05 AM EDT - 2 months ago

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

May 12, 2025, 6:00 AM EDT - 2 months ago

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

May 1, 2025, 8:00 AM EDT - 3 months ago

Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference

Apr 14, 2025, 8:04 AM EDT - 3 months ago

Apogee Therapeutics: Engineering Biologic Dominance

Mar 3, 2025, 12:16 PM EST - 5 months ago

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Mar 3, 2025, 6:05 AM EST - 5 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Mar 3, 2025, 6:00 AM EST - 5 months ago

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Feb 28, 2025, 4:00 PM EST - 5 months ago

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Feb 25, 2025, 7:30 AM EST - 5 months ago

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Feb 3, 2025, 7:00 AM EST - 6 months ago

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Jan 29, 2025, 7:30 AM EST - 6 months ago

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Dec 2, 2024, 6:00 AM EST - 8 months ago

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Nov 29, 2024, 1:00 PM EST - 8 months ago

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Nov 18, 2024, 7:30 AM EST - 9 months ago

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Nov 10, 2024, 9:55 AM EST - 9 months ago

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Nov 4, 2024, 7:30 AM EST - 9 months ago

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Oct 16, 2024, 7:00 AM EDT - 10 months ago

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

Sep 12, 2024, 7:00 AM EDT - 11 months ago

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

Sep 9, 2024, 7:00 AM EDT - 11 months ago

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

Aug 12, 2024, 6:30 AM EDT - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

Jun 18, 2024, 10:05 AM EDT - 1 year ago

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

May 28, 2024, 7:30 AM EDT - 1 year ago

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

May 23, 2024, 7:30 AM EDT - 1 year ago

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

May 15, 2024, 4:01 PM EDT - 1 year ago

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

May 13, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

May 6, 2024, 8:00 AM EDT - 1 year ago

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Mar 12, 2024, 4:01 PM EDT - 1 year ago

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million

Mar 7, 2024, 6:49 PM EST - 1 year ago

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

Mar 6, 2024, 4:13 PM EST - 1 year ago

Apogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 Advancement

Mar 5, 2024, 4:23 PM EST - 1 year ago

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Mar 5, 2024, 1:28 PM EST - 1 year ago

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management

Mar 5, 2024, 6:10 AM EST - 1 year ago

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 5, 2024, 6:00 AM EST - 1 year ago

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc

Mar 4, 2024, 4:01 PM EST - 1 year ago

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

Jan 2, 2024, 7:30 AM EST - 1 year ago

Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 7:30 AM EST - 1 year ago

Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results

Sep 27, 2023, 8:42 AM EDT - 2 years ago

Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress

Sep 14, 2023, 7:30 AM EDT - 2 years ago

Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day

Aug 29, 2023, 8:00 AM EDT - 2 years ago

Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics

Aug 28, 2023, 7:30 AM EDT - 2 years ago

Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 8:14 AM EDT - 2 years ago

Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing

Aug 21, 2023, 7:30 AM EDT - 2 years ago

Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board

Aug 7, 2023, 7:30 AM EDT - 2 years ago

Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

rxptgh Jul. 29 at 7:25 AM

$APGE undervalued Under followed

0 · Reply

StockHunter75 Jul. 28 at 6:28 PM

$APGE bought the dip.

0 · Reply

idk_idk Jul. 28 at 2:52 PM

$APGE gonna be a long wait, but worth it hopefully

0 · Reply

fezziwig2018 Jul. 24 at 3:36 PM

All of my $ATPC and $APGE eventually found its way into $IXHL last week -Cost basis $0.48 - will add on any pullbacks - though I don’t anticipate any.

1 · Reply

gc358 Jul. 23 at 3:44 PM

$APGE With 8.7M short shares comprising 23% of the float, this is primed for a squeeze if we can get some buying pressure.

0 · Reply

StockHunter75 Jul. 23 at 2:38 PM

$APGE buying more.

0 · Reply

amda Jul. 21 at 6:41 PM

$APGE slow and steady upward from under $39..

0 · Reply

amda Jul. 21 at 3:36 PM

$APGE a steal under $40...

0 · Reply

StockHunter75 Jul. 21 at 2:06 PM

$APGE Bullish. Buy the dips

0 · Reply

HodlMaBeer Jul. 21 at 1:47 PM

$APGE release the lion

0 · Reply

PhishTourFunds Jul. 18 at 5:07 PM

$APGE

0 · Reply

rxptgh Jul. 16 at 6:18 PM

$APGE

0 · Reply

Deekay1 Jul. 15 at 8:24 PM

$APGE dead in the water till next PR...

0 · Reply

LadsAndGents Jul. 15 at 7:32 PM

$APGE can it close above 37.77

1 · Reply

11hundred Jul. 15 at 7:29 PM

$APGE and $TMDE my biggest losses so far -50+%... Gonna hold for a few more weeks.

2 · Reply

amda Jul. 15 at 6:38 PM

$APGE bot 37.40

0 · Reply

Deekay1 Jul. 15 at 7:40 AM

$APGE I don't see where this is what's up .56 cents in after hours trading?!? Where did stock to its get that price bump after hours?!?

0 · Reply

chuckjackson Jul. 14 at 9:12 PM

$APGE my guess is in the long-term, this stock will do just fine. Best in class results. Quarterly shots. Something like $650M cash which suggests liquidity is fine and near-term offering is not needed. Unfortunately, it is still in the clinical stage phase and we won't hear about new results until 2026? It shouldn't drop too much or it will become a buyout candidate but it will get pushed around until we get closer to the next readout

0 · Reply

amda Jul. 12 at 8:25 PM

$APGE new upgrade after Friday's close: Apogee Therapeutics price target raised to $115 from $100 at BTIG Jul 11, 2025, 06:10 PM A- BTIG raised the firm’s price target on Apogee Therapeutics (APGE) to $115 from $100 and keeps a Buy rating on the shares. The firm notes that the new EASI-75 watermark for Biologics in Atopic Dermatitis exceeded its expectations and supports a market-leading profile, the analyst tells investors in a research note.

0 · Reply

Bug1 Jul. 12 at 2:36 PM

$APGE the daily spreads r quite high!

0 · Reply

BallKnowerR Jul. 11 at 3:42 PM

$APGE This is too low at the moment. Building a healthy starter position. Lots of runway here, will keep adding over the coming weeks.

0 · Reply

amda Jul. 11 at 3:39 PM

$APGE CEM97 - you ok, little buddy? this is green with the market down 300....I'm worried about you and those puts..

0 · Reply

1.0.0